Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized phase III study comparing erlotinib plus bevacizumab to erlotinib alone in patients with previously untreated non-small cell lung cancer harboring EGFR mutation (NEJ026)

Next Previous
Trial Profile

Randomized phase III study comparing erlotinib plus bevacizumab to erlotinib alone in patients with previously untreated non-small cell lung cancer harboring EGFR mutation (NEJ026)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 31 May 2020 Results of meta-analysis of randomized trials (ARTEMIS, NEJ026, J025667, Stinchcombe et al, RELAY) comparing VEGF inhibitor plus erlotinib with erlotinib alone in first line treatment for advanced NSCLC harbouring EGFR mutation presented at the 56th Annual Meeting of the American Society of Clinical Oncology
  • 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
  • 10 Sep 2019 Results assessing plasma EGFR mutations as preplanned analysis, presented at the 20th World Conference on Lung Cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top